Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

Department of Cancer Biology, Pfizer Global Research and Development, La Jolla Laboratories, 10724 Science Center Drive, San Diego, CA 92121, USA.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.45). 04/2009; 53(6):2544-52. DOI: 10.1128/AAC.01599-08
Source: PubMed

ABSTRACT PF-00868554 is a nonnucleoside inhibitor of the hepatitis C virus (HCV) RNA polymerase, which exerts its inhibitory effect by binding to the thumb base domain of the protein. It is a potent and selective inhibitor, with a mean 50% inhibitory concentration of 0.019 microM against genotype 1 polymerases and a mean 50% effective concentration (EC(50)) of 0.075 microM against the genotype 1b-Con1 replicon. To determine the in vitro antiviral activity of PF-00868554 against various HCV strains, a panel of chimeric replicons was generated, in which polymerase sequences derived from genotype 1a and 1b clinical isolates were cloned into the 1b-Con1 subgenomic reporter replicon. Our results indicate that PF-00868554 has potent in vitro antiviral activity against a majority (95.8%) of genotype 1a and 1b replicons, with an overall mean EC(50) of 0.059 microM. PF-00868554 showed no cytotoxic effect in several human cell lines, up to the highest concentration evaluated (320 microM). Furthermore, the antiviral activity of PF-00868554 was retained in the presence of human serum proteins. An in vitro resistance study of PF-00868554 identified M423T as the predominant resistance mutation, resulting in a 761-fold reduction in susceptibility to PF-00868554 but no change in susceptibility to alpha interferon and a polymerase inhibitor that binds to a different region. PF-00868554 also showed good pharmacokinetic properties in preclinical animal species. Our results demonstrate that PF-00868554 has potent and broad-spectrum antiviral activity against genotype 1 HCV strains, supporting its use as an oral antiviral agent in HCV-infected patients.

Download full-text


Available from: M. Angelica Linton, Apr 15, 2015
  • Source
    • "utation , resulting in a 761 - fold reduction in susceptibility to filibuvir , but no change in susceptibility to IFN - α and a polymerase inhibitor that binds to a different region . Filibuvir also showed good pharmacokinetic properties in preclinical animal species , revealing promising oral bioavailability in both rodent and nonrodent species ( Shi et al . , 2009 ) . Also , filibuvir seemed not to affect any of the major CYP isoforms ( IC 50 >30 µmol / L for 1A2 , 2C8 , 2D6 , 3A4 , 2C9 , and 2C19 ) ( Li et al . , 2009 ) ."
    [Show abstract] [Hide abstract]
    ABSTRACT: Infection with hepatitis C virus (HCV) affects approximately 170 million people worldwide. However, no vaccine or immunoglobulin is currently available for the prevention of HCV infection. The standard of care (SOC) involving pegylated interferon-α (PEG-IFN α) plus ribavirin (RBV) for 48 weeks results in a sustained virologic response in less than 50% of patients with chronic hepatitis C genotype 1, the most prevalent type of HCV in North America and Europe. Recently, reliable in vitro culture systems have been developed for accelerating antiviral therapy research, and many new specifically targeted antiviral therapies for hepatitis C (STAT-C) and treatment strategies are being evaluated in clinical trials. These new antiviral agents are expected to improve present treatment significantly and may potentially shorten treatment duration. The aim of this review is to summarize the current developments in new anti-HCV drugs.
    Journal of Zhejiang University SCIENCE B 01/2012; 13(1):56-82. DOI:10.1631/jzus.B1100120 · 1.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Basic to the development of new specific anti-hepatitis C virus drugs is the understanding of the viral life cycle, in particular the genomic organization and the polyprotein processing. Major progress in this field was achieved with the development of subgenomic and more recently full genomic replicon systems. The hepatitis C virus genome is a single-stranded RNA molecule that contains a single open reading frame encoding a polyprotein of about 3,000 amino acids. The polyprotein is subsequently processed at the level of the endoplasmic reticulum by cellular and viral proteases to yield four structural and six nonstructural proteins. The open reading frame is flanked by 5′ and 3′ untranslated regions. NS3 and NS4A are cleaved by the catalytic activity of the NS3 protease domain. The NS3 protease domain is responsible to complete the polyprotein processing down to NS4B, NS5A, and NS5B. Despite the fact that the catalytic site is a shallow and largely hydrophobic groove and therefore very difficult to target, several compounds have been successfully designed. The NS5B RNA-dependent RNA polymerase is the key enzyme for synthesis of a complementary minus-strand RNA using the genome as template, and the subsequent synthesis of genomic plus-strand RNA from this minus-strand RNA template. The active site of the enzyme is a target for nucleoside/nucleotide analogue inhibitors. Nonnucleoside inhibitors, reported to bind at various sites, may act by blocking the enzyme in the initiation mode through inhibition of a conformational change needed to proceed with elongation.Copyright © 2011 S. Karger AG, Basel
  • [Show abstract] [Hide abstract]
    ABSTRACT: A combination of ceramic substrate technology with thin film processes will be presented. Thick film hybrids are used for the bottom layers and a thin film metallization layer is deposited on top for the redistribution of the signal lines. For the evaluation of this combined technology test samples of multilayer ceramic substrates were manufactured. Polymer films having a low dielectric constants and thin film copper were used to fabricate the high density interconnection layer. Photosensitive polymers were selected to reduce the number of processing steps for via formation. Photo-BCB is recommended for the dielectric layers because planarization of the ceramic substrate is the most critical issue for the high density metallization. For thicker photo-BCB films a tank development process was installed at TUB/Fraunhofer-IZM which has the unique feature that the development time is nearly independent of the layer thickness. The reliability of the substrates was proofed by thermal cycling
    Advanced Packaging Materials, 1998. Proceedings. 1998 4th International Symposium on; 04/1998
Show more